CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Yuhan Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Yuhan Corp
74, Noryangjin-ro, Dongjak-gu
Phone: +82 28280181p:+82 28280181 SEOUL, 06927  South Korea Ticker: 000100000100

Business Summary
Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Co-President, Chief Executive Officer, Director Wuk JeCho 68 1/1/2023 4/1/2009
Co-President, Director Yeol HongKim 65 3/15/2024 3/15/2024
Vice President, Director Byeong ManLee 65 1/1/2022 1/1/2015
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ImmuneOncia Therapeutics Inc. Wins-tower 6F, 15, Pangyo-ro 228beon-gil Seongnam-si Gyeonggi-do South Korea

Business Names
Business Name
0001
000100
000105
000107
ImmuneOncia Therapeutics Inc.
Yuhan Corporation

General Information
Number of Employees: 1,594 (As of 12/31/2015)
Outstanding Shares: 73,511,266 (As of 1/19/2024)
Shareholders: 81,654
Stock Exchange: KRX
Fax Number: +82 28280050


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024